Track topics on Twitter Track topics that are important to you
In The Lancet, Robert Croop and colleagues1 present a carefully designed phase 3 trial on an oral disintegrating tablet (ODT) of rimegepant for the acute treatment of migraine among 1375 patients (85% female, mean age 40·2 years [SD 12·0]). The trial was positive, showing an increase in relief from headache pain among the group receiving rimegepant at 2 h after dosing (10% over placebo) and improvement in the most bothersome symptoms, which included photophobia and nausea (8% over placebo). The onset was reported to be slightly faster than that of other gepants (first positive effect at 1 h for rimegepant vs 2 h for telcagepant) and the effect on the lower side (10% for rimegepant vs a mean of 17% in four trials on telcagepant), but the duration was up to 48 h.
Original Article: [Comment] Rimegepant oral disintegrating tablet for migraineNEXT ARTICLE
Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...
Pain is a feeling (sharp or dull) triggered in the nervous system which can be transient or constant. Pain can be specific to one area of the body eg back, abdomen or chest or more general all over the body eg muscles ache from the flu. Without pain ...